Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Candice Tung

Internal Medicine Las Vegas, NV Medical Doctor

NPI 1063598183 CMS profile 3168

7395 S Pecos Rd Ste 102, Las Vegas, NV 89120

Open in the dashboard

General payments

$4,482

258 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Candice Tung of Las Vegas, NV is reported in the CMS Open Payments database as having received $4,482 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $945 41
2024 General $832 56
2023 General $613 37
2022 General $601 46
2021 General $364 18
2020 General $603 29
2019 General $524 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Candice Tung
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Candice Tung were reported at $945. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Candice Tung Internal Medicine median Middle half National median
2019 $524 $159 $48–$570 $163
2020 $603 $119 $33–$402 $114
2021 $364 $135 $37–$521 $132
2022 $601 $141 $42–$496 $149
2023 $613 $149 $45–$519 $160
2024 $832 $154 $47–$537 $164
2025 $945 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $764 56 payments
  2. Amgen Inc. $641 32 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $485 36 payments
  4. AbbVie, Inc. $289 22 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $287 16 payments
  6. Novartis Pharmaceuticals Corporation $286 12 payments
  7. Lilly USA, LLC $244 18 payments
  8. Pfizer Inc. $239 13 payments
  9. Arbor Pharmaceuticals, Inc. $201 9 payments
  10. Edwards Lifesciences Corporation $131 1 payment
  11. Other $915 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,368 255 payments
  2. Education $114 3 payments
Products named General payments · program years 2019–2025
  1. Kerendia $485 36 payments
  2. Ozempic $404 30 payments
  3. RYBELSUS $404 30 payments
  4. EVENITY $243 12 payments
  5. Prolia $224 11 payments
  6. Repatha $220 15 payments
  7. LEQVIO $214 9 payments
  8. MOUNJARO $188 14 payments
  9. Otezla $160 8 payments
  10. JARDIANCE $156 9 payments
  11. Other $3,220 184 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 98 drugs

Part D claims

3,243

Median for Internal Medicine: 777

Drug cost

$424,719

Median for Internal Medicine: $73,373

Branded share of claims

29.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 79 $79,345
Ozempic Semaglutide Brand 56 $63,435
Eliquis Apixaban Brand 46 $45,403
Rybelsus Semaglutide Brand 31 $42,572
Jardiance Empagliflozin Brand 24 $27,883
Xarelto Rivaroxaban Brand 14 $21,590
Repatha Sureclick Evolocumab Brand 19 $17,091
Linzess Linaclotide Brand 15 $16,149
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 19 $14,342
Nexlizet Bempedoic Acid/Ezetimibe Brand 20 $14,116

The 10 drugs with the highest cost, of 98 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$156,148

Of which drugs: $65,132

Medicare patients

192

Average age 76

Services billed

5,667

123 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 46%
Diabetes 39%
Osteoporosis 27%
Ischemic heart disease 24%
Depression 18%
Atrial fibrillation 16%
Chronic kidney disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 18 1,560 $30,147
Pcv20 vaccine im 90677 Office 27 27 $7,877
Vaccine for influenza for injection into muscle 90653 Office 78 78 $5,125
Sarscv2 vac 30mcg trs-suc im 91320 Office 27 27 $4,125

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $239
$239 12 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $69
  • Lilly USA, LLC $34
$103 24 —
MOUNJARO
  • Lilly USA, LLC $94
$94 79 —
ZEPBOUND
  • Lilly USA, LLC $66
$66 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record